Compositions for preventing and treating infection
Compositions for preventing and treating infection
Composition including ace-K, cyclamate or saccharin, or a chemically related derivative of any of these, for use in increasing the susceptibility of bacteria to an antibiotic. Composition may render an antibiotic resistance bacterium sensitive to the antibiotic. The composition may comprise an anti-biotic (e.g. beta-lactam, carbapenem, aminoglycoside, polymyxin). Composition may be formulated for application to a patients skin (e.g. as a liquid, cream, ointment, gel or hydrogel) and may be incorporated into a wound dressing. The composition may be suitable for inhalation (e.g. aerosolised or dry powder form). The composition may be formulated for intraveneous administration or for oral administration. The acesulfame-potassium, sodium cyclohexylsulfamate, sarrcharin may be present at less than 15 %w/v, such as below 1 %w/v and, preferably, are below their minimum inhibitory concentration. The bacterial species may be P. aeruginosa or A. baumannii. Also claimed is the composition for use in disrupting the membrane of the bacteria.
GB2635253
Intellectual Property Office
7 May 2025
Mccarthy, Ronan
0b2cf2e0-b0ff-4c92-aa04-92d91182d1f2
Mccarthy, Ronan
(Inventors)
(2025)
Compositions for preventing and treating infection.
GB2635253.
Abstract
Composition including ace-K, cyclamate or saccharin, or a chemically related derivative of any of these, for use in increasing the susceptibility of bacteria to an antibiotic. Composition may render an antibiotic resistance bacterium sensitive to the antibiotic. The composition may comprise an anti-biotic (e.g. beta-lactam, carbapenem, aminoglycoside, polymyxin). Composition may be formulated for application to a patients skin (e.g. as a liquid, cream, ointment, gel or hydrogel) and may be incorporated into a wound dressing. The composition may be suitable for inhalation (e.g. aerosolised or dry powder form). The composition may be formulated for intraveneous administration or for oral administration. The acesulfame-potassium, sodium cyclohexylsulfamate, sarrcharin may be present at less than 15 %w/v, such as below 1 %w/v and, preferably, are below their minimum inhibitory concentration. The bacterial species may be P. aeruginosa or A. baumannii. Also claimed is the composition for use in disrupting the membrane of the bacteria.
This record has no associated files available for download.
More information
Published date: 7 May 2025
Identifiers
Local EPrints ID: 509361
URI: http://eprints.soton.ac.uk/id/eprint/509361
PURE UUID: 85908a57-21fe-447a-b57e-562af8e93eab
Catalogue record
Date deposited: 19 Feb 2026 17:47
Last modified: 20 Feb 2026 03:14
Export record
Contributors
Inventor:
Ronan Mccarthy
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics